Get Premium to unlock powerful stock data

EcoR1 Capital, LLC Buys Apellis Pharmaceuticals Inc, CRISPR Therapeutics AG, ACADIA Pharmaceuticals Inc, Sells Mirati Therapeutics Inc, Shattuck Labs Inc,

Author's Avatar
Feb 15, 2022
Article's Main Image
San Francisco, CA, based Investment company EcoR1 Capital, LLC (Current Portfolio) buys Apellis Pharmaceuticals Inc, CRISPR Therapeutics AG, ACADIA Pharmaceuticals Inc, Atea Pharmaceuticals Inc, 2seventy bio Inc, sells Mirati Therapeutics Inc, Shattuck Labs Inc, , Nurix Therapeutics Inc, Corvus Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, EcoR1 Capital, LLC. As of 2021Q4, EcoR1 Capital, LLC owns 76 stocks with a total value of $3.1 billion. These are the details of the buys and sells.

For the details of EcoR1 Capital, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/ecor1+capital%2C+llc/current-portfolio/portfolio

These are the top 5 holdings of EcoR1 Capital, LLC
  1. Prothena Corp PLC (PRTA) - 11,284,280 shares, 17.76% of the total portfolio.
  2. AnaptysBio Inc (ANAB) - 7,521,024 shares, 8.33% of the total portfolio.
  3. Arcus Biosciences Inc (RCUS) - 5,523,358 shares, 7.12% of the total portfolio. Shares added by 7.83%
  4. Xencor Inc (XNCR) - 4,906,106 shares, 6.27% of the total portfolio.
  5. Apellis Pharmaceuticals Inc (APLS) - 4,033,882 shares, 6.08% of the total portfolio. New Position
New Purchase: Apellis Pharmaceuticals Inc (APLS)

EcoR1 Capital, LLC initiated holding in Apellis Pharmaceuticals Inc. The purchase prices were between $30.74 and $49.16, with an estimated average price of $39.7. The stock is now traded at around $47.070000. The impact to a portfolio due to this purchase was 6.08%. The holding were 4,033,882 shares as of 2021-12-31.

New Purchase: CRISPR Therapeutics AG (CRSP)

EcoR1 Capital, LLC initiated holding in CRISPR Therapeutics AG. The purchase prices were between $70.09 and $102.99, with an estimated average price of $86.82. The stock is now traded at around $60.970000. The impact to a portfolio due to this purchase was 2.6%. The holding were 1,077,483 shares as of 2021-12-31.

New Purchase: ACADIA Pharmaceuticals Inc (ACAD)

EcoR1 Capital, LLC initiated holding in ACADIA Pharmaceuticals Inc. The purchase prices were between $16.79 and $27.09, with an estimated average price of $20.21. The stock is now traded at around $27.280000. The impact to a portfolio due to this purchase was 2.28%. The holding were 3,060,593 shares as of 2021-12-31.

New Purchase: Atea Pharmaceuticals Inc (AVIR)

EcoR1 Capital, LLC initiated holding in Atea Pharmaceuticals Inc. The purchase prices were between $7.67 and $44.59, with an estimated average price of $14.96. The stock is now traded at around $6.420000. The impact to a portfolio due to this purchase was 1.53%. The holding were 5,376,134 shares as of 2021-12-31.

New Purchase: Sage Therapeutics Inc (SAGE)

EcoR1 Capital, LLC initiated holding in Sage Therapeutics Inc. The purchase prices were between $37.06 and $47.11, with an estimated average price of $41.81. The stock is now traded at around $43.500000. The impact to a portfolio due to this purchase was 1.28%. The holding were 940,636 shares as of 2021-12-31.

New Purchase: Pardes Biosciences Inc (PRDS)

EcoR1 Capital, LLC initiated holding in Pardes Biosciences Inc. The purchase prices were between $10.62 and $17.02, with an estimated average price of $13.8. The stock is now traded at around $10.290000. The impact to a portfolio due to this purchase was 0.83%. The holding were 1,597,139 shares as of 2021-12-31.

Added: 2seventy bio Inc (TSVT)

EcoR1 Capital, LLC added to a holding in 2seventy bio Inc by 616.65%. The purchase prices were between $13.77 and $42.56, with an estimated average price of $31.18. The stock is now traded at around $15.200000. The impact to a portfolio due to this purchase was 1.35%. The holding were 1,917,063 shares as of 2021-12-31.

Added: Protagonist Therapeutics Inc (PTGX)

EcoR1 Capital, LLC added to a holding in Protagonist Therapeutics Inc by 82.83%. The purchase prices were between $17.63 and $37.1, with an estimated average price of $31.91. The stock is now traded at around $28.730000. The impact to a portfolio due to this purchase was 1.3%. The holding were 2,639,706 shares as of 2021-12-31.

Added: Galapagos NV (GLPG)

EcoR1 Capital, LLC added to a holding in Galapagos NV by 42.70%. The purchase prices were between $47.03 and $57.12, with an estimated average price of $52.17. The stock is now traded at around $66.780000. The impact to a portfolio due to this purchase was 1.17%. The holding were 2,224,403 shares as of 2021-12-31.

Added: Relay Therapeutics Inc (RLAY)

EcoR1 Capital, LLC added to a holding in Relay Therapeutics Inc by 28.43%. The purchase prices were between $26 and $37.03, with an estimated average price of $31.65. The stock is now traded at around $21.450000. The impact to a portfolio due to this purchase was 0.39%. The holding were 1,779,084 shares as of 2021-12-31.

Added: Voyager Therapeutics Inc (VYGR)

EcoR1 Capital, LLC added to a holding in Voyager Therapeutics Inc by 697.66%. The purchase prices were between $2.47 and $5.55, with an estimated average price of $3.41. The stock is now traded at around $3.670000. The impact to a portfolio due to this purchase was 0.27%. The holding were 3,557,507 shares as of 2021-12-31.

Sold Out: Mirati Therapeutics Inc (MRTX)

EcoR1 Capital, LLC sold out a holding in Mirati Therapeutics Inc. The sale prices were between $132.01 and $190.29, with an estimated average price of $154.69.

Sold Out: Shattuck Labs Inc (STTK)

EcoR1 Capital, LLC sold out a holding in Shattuck Labs Inc. The sale prices were between $8.36 and $20.31, with an estimated average price of $13.53.

Sold Out: (DRNA)

EcoR1 Capital, LLC sold out a holding in . The sale prices were between $19.26 and $38.25, with an estimated average price of $29.18.

Sold Out: Corvus Pharmaceuticals Inc (CRVS)

EcoR1 Capital, LLC sold out a holding in Corvus Pharmaceuticals Inc. The sale prices were between $2.34 and $5.31, with an estimated average price of $3.84.

Sold Out: bluebird bio Inc (BLUE)

EcoR1 Capital, LLC sold out a holding in bluebird bio Inc. The sale prices were between $8.96 and $16.31, with an estimated average price of $11.77.

Sold Out: Cyclerion Therapeutics Inc (CYCN)

EcoR1 Capital, LLC sold out a holding in Cyclerion Therapeutics Inc. The sale prices were between $1.56 and $2.95, with an estimated average price of $2.35.



Here is the complete portfolio of EcoR1 Capital, LLC. Also check out:

1. EcoR1 Capital, LLC's Undervalued Stocks
2. EcoR1 Capital, LLC's Top Growth Companies, and
3. EcoR1 Capital, LLC's High Yield stocks
4. Stocks that EcoR1 Capital, LLC keeps buying
Rating:
0 / 5 (0 votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles